NanoImmunoRT
Financiado
Synergizing enhanced radiotherapy with tumor-associated macrophages-targeted imm...
Synergizing enhanced radiotherapy with tumor-associated macrophages-targeted immunotherapy in glioblastoma with multimodal therapeutic nanoparticles
In glioblastoma (GBM), intrinsic and environmental factors are limiting the efficacy of radiation therapy (RT) and immunotherapy. These factors include intrinsic cancer cells resistance, hypoxia, and the presence of immunosuppress...
In glioblastoma (GBM), intrinsic and environmental factors are limiting the efficacy of radiation therapy (RT) and immunotherapy. These factors include intrinsic cancer cells resistance, hypoxia, and the presence of immunosuppressive cells such as tumor–associated macrophages (TAMs).
Considering these current limitations for RT efficacy and the specific deleterious role of TAMs in GBM, I designed an original therapeutic strategy combining enhanced RT and TAMs reprogramming with toll-like receptors (TLRs) agonists to synergize direct cytotoxicity to tumors cells at low radiation doses with immunotherapy for both local and recurrent tumor rejection. For this, I will use relevant radio-sensitizing moieties for GBM: high Z atoms which can efficiently absorb, scatter, and emit radiation energy and catalase, an enzyme capable of converting H2O2 to oxygen in the tumor microenvironment (TME). It will be simultaneously applied with the combination of the TLRs agonists poly(I:C) and resiquimod, which will be used to re-educate TAMs and prepare the TME to a strong anti-tumoral immune response. The selected molecules will be incorporated in a new Multimodal Therapeutic NanoParticle (MTNP), based on a nanosized zeolite structure, allowing to combine the two approaches in a unique particle.
The MTNPs will be tested in vitro and in vivo in murine model of GBM and patient-derived samples, to verify their effectiveness in enhancing RT and reeducating TAMs, and their effect on tumor growth. The present multidisciplinary research program aims at supporting greater progress in the treatment of brain tumors and ultimately leading to improved outcomes for cancer patients.
ver más
Duración del proyecto: 31 meses
Fecha Inicio: 2023-05-11
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-11
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
125K€
Líder del proyecto
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5